University of Pennsylvania

Novartis Ag

Marco Ruella

Jennifer Brogdon

Saar Gill

Carl H June

David Jonathan Glass

Joan Mannick

Leon Murphy

Ming Lei

Andreas Loew

Michael C Milone

Qilong Wu

Yongqiang Wang

Lu Huang

Jimin Zhang

Na Li

Barbara Brannetti

David L Porter

Saad Kenderian

Boris Engels

Reshma Singh

Hilmar Erhard Ebersbach

Jennifer Bordeaux

Brian Walter Granda

Jiquan Zhang

Li Zhou

Celeste Richardson

Naveen Kumar Dakappagari

Ju Young Kim

Elena Orlando

Hans Bitter

Gabriela Plesa

Steven Highfill

Regina M Young

Eugene Choi

Heather Huet

Daniel J Powell

Carla Guimaraes

Marcela V Maus

John C Byrd

Anna Vulpetti

Thai Tran

Avery D Posey

Natarajan Muthusamy

Mariusz Wasik

Amy Jo Johnson

Daniela Angst

Jason A Dubovsky

William Raj Sellers

Carla Patricia Pinto Guimaraes

Joseph Fraietta

Joseph A Fraietta

François Gessier

Jennifer Mary Bordeaux

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell

The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out.

Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

Treatment of cancer using humanized anti-BCMA chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain

Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain

The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.

Treatment of cancer using a CD123 chimeric antigen receptor

Anti-BCMA chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.

Treatment of cancer using anti-CD19 Chimeric Antigen Receptor

Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor

Growing community of inventors

Ardmore, PA, United States of America

Marco Ruella